Expression of galectin-3, nm-23, and cyclooxygenase-2 could potentially discriminate between benign and malignant pheochromocytoma

American Journal of Clinical Pathology

Volumn 135, Issue 3, 2011, Pages 454-460

  Saffar, Hiva ^a   Sanii, Sanaz ^a   Heshmat, Ramin ^a   Haghpanah, Vahid ^a   Larijani, Bagher ^a   Rajabiani, Afsaneh ^a   Azimi, Sima ^a   Tavangar, Seyed Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cyclooxygenase 2; Galectin 3; Nm 23; Pheochromocytoma

Indexed keywords

CYCLOOXYGENASE 2; GALECTIN 3; NUCLEOSIDE DIPHOSPHATE KINASE NM23; PTGS2 PROTEIN, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; ADRENAL TUMOR; DISEASE COURSE; EARLY DIAGNOSIS; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; PREDICTIVE VALUE;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; CHILD; CYCLOOXYGENASE 2; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; FEMALE; GALECTIN 3; HUMANS; MALE; MIDDLE AGED; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; PHEOCHROMOCYTOMA; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79954439197     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPI8AJLUZ3CZLN     Document Type: Article

References (41)

1. Wieneke JA, Lack EE. The adrenal gland. In: Silverberg SG, DeLellis RA, Frable WJ, et al, eds. Silverberg's Principles and Practice of Surgical Pathology and Cytopathology. 4th ed. New York, NY: Churchill Livingstone; 2006: 2191-2194.
2. Lack EE. Tumors of the adrenal gland. In: Fletcher CDM, ed. Diagnostic Histopathology of Tumors. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007: 1109-1115.
3. DeLellis RA, Mangray S. The adrenal glands. In: Mills SE, Carter D, Greenson JK, et al, eds. In: Carter D, Greenson JK, Oberman HA, et al, eds. Sternberg's Diagnostic Surgical Pathology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010: 576-581.
4. Rosai J. Adrenal gland and other paraganglia. In: Rosai J, ed. Rosai and Ackerman's Surgical Pathology. 9th ed. St Louis, MO: Mosby; 2004: 1136-1139.
5. Weiss LM. Adrenal gland. In: Weidner N, Cote RJ, Suster S, et al. Modern Surgical Pathology. Philadelphia, PA: Saunders; 2003: 1765-1767.
6. Tavangar SM, Shojaee A, Moradi Tabrizi H, et al. Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma. Pathol Res Pract. 2010;206:305-309. doi:10.1016/j.prp. 2010.01.007.
7. Ohta S, Lai EW, Pang AL, et al. Down-regulation of metastasis suppressor genes in malignant pheochromocytoma. Int J Cancer. 2005;114:139-143. (Pubitemid 40194319)
8. Cipollini G, Berti A, Fiore L, et al. Down-regulation of the nm23.h1 gene inhibits cell proliferation. Int J Cancer. 1997;73:297-302. (Pubitemid 27448834)
9. Howlett AR, Petersen OW, Steeg PS, et al. A novel function for the nm23-H1 gene: overexpression in human breast carcinoma cells leads to the formation of basement membrane and growth arrest. J Natl Cancer Inst. 1994;86:1838-1844.
10. Albertazzi E, Cajone F, Leone BE, et al. Expression of metastasis-associated genes h-mts1 (S100A4) and nm23 in carcinoma of breast is related to disease progression. DNA Cell Biol. 1998;17:335-342. (Pubitemid 28188838)
11. Zhao H, Jhanwar-Uniyal M, Datta PK, et al. Expression profile of genes associated with antimetastatic gene: nm23-mediated metastasis inhibition in breast carcinoma cells. Int J Cancer. 2004;109:65-70. (Pubitemid 38160663)
12. Liu YB, Gao SL, Chen XP, et al. Expression and significance of heparanase and nm23-H1 in hepatocellular carcinoma.. World J Gastroenterol. 2005;11:1378-1381.
13. Liu Y, Chen X, Peng S, et al. The expression and significance of heparanase and nm23-H1 in hepatocellular carcinoma [in Chinese]. Zhonghua Yi Xue Za Zhi. 2002;82:1553-1556.
14. Nie Q, Zhou QH, Zhu W, et al. nm23-H1 gene inhibits lung cancer cell invasion through down-regulation of PKC signal pathway [in Chinese]. Zhonghua Zhong Liu Za Zhi. 2006;28:334-336.
15. Che GW, Zhou QH, Zhu W, et al. Molecular mechanism of reversing metastatic phenotype in human high-metastatic large cell lung cancer cell line L9981 by nm23-H1 [in Chinese]. Ai Zheng. 2005;24:278-284.
16. Hsu NY, Chen CY, Hsu CP, et al. Prognostic significance of expression of nm23-H1 and focal adhesion kinase in non-small cell lung cancer. Oncol Rep. 2007;18:81-85.
17. Gao QL, Ma D, Meng L, et al. Association between nm23-H1 gene expression and metastasis of ovarian carcinoma. Ai Zheng. 2004;23:650-654.
18. Mandai M, Konishi I, Koshiyama M, et al. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression. Cancer Res. 1994;54:1825-1830. (Pubitemid 24116194)
19. Chow NH, Liu HS, Chan SH. The role of nm23-H1 in the progression of transitional cell bladder cancer. Clin Cancer Res. 2000;6:3595-3599.
20. Cui S, Tang TL, Li X, et al. The effects of nm23-H1 gene cell transfection on abilities of invasion, adhesion and chemotherapeutic sensitivity of bladder cancer T-24 cell line [in Chinese]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2007;38:788-791.
21. Ohba K, Miyata Y, Koga S, et al. Expression of nm23-H1 gene product in sarcomatous cancer cells of renal cell carcinoma: correlation with tumor stage and expression of matrix metalloproteinase-2, matrix metalloproteinase-9, sialyl Lewis X, and c-erbB-2. Urology. 2005;65:1029-1034. (Pubitemid 40693017)
22. Rodrigues S, Bruyneel E, Rodrigue CM, et al. Cyclooxygenase 2 and carcinogenesis [in French]. Bull Cancer. 2004;91(suppl 2):S61-S76.
23. Zhang X, Miao X, Tan W, et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology. 2005;129:565-576. (Pubitemid 41096644)
24. Singh B, Berry JA, Shoher A, et al. COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol. 2005;26:1393-1399.
25. Larkins TL, Nowell M, Singh S, et al. Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer. 2006;6:181. doi:10.1186/1471-2407-6-181. (Pubitemid 44335961)
26. Kwan ML, Habel LA, Slattery ML, et al. NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control. 2007;18:613-620. (Pubitemid 46883678)
27. Singh B, Berry JA, Shoher A, et al. COX-2 induces IL-11 production in human breast cancer cells. J Surg Res. 2006;131:267-275.
28. 2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth. Mod Pathol. 2005;18:221-227. (Pubitemid 40188629)
29. Popovtzer A, Morgenstein S, Roizman P, et al. Cyclooxygenase-2 expression in medullary thyroid carcinoma. Head Neck. 2007;29:559-563. (Pubitemid 47324772)
30. Bell CD, Vidal S, Kovacs K, et al. An immunohistochemical survey of nine cases of medullary carcinoma of thyroid including reactivity for COX-1 and COX-2 enzymes. Endocr Pathol. 2002;13:331-339. (Pubitemid 36237987)
31. Panguluri RC, Long LO, Chen W, et al. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis. 2004;25:961-966. (Pubitemid 38886082)
32. Brown JR, DuBois RN. Cyclooxygenase as a target in lung cancer. Clin Cancer Res. 2004;10(12 pt 2):4266s-4269s. (Pubitemid 38812460)
33. Salmenkivi K, Haglund C, Ristimäki A, et al. Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. J Clin Endocrinol Metab. 2001;86:5615-5619. (Pubitemid 33070296)
34. Jakubiak-Wielganowicz M, Kubiak R, Sygut J, et al. Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma. Pol J Pathol. 2003;54:111-115. (Pubitemid 37151022)
35. Puglisi F, Minisini AM, Barbone F, et al. Galectin-3 expression in non-small cell lung carcinoma. Cancer Lett. 2004;212:233-239. (Pubitemid 38997979)
36. Szöke T, Kayser K, Trojan I, et al. The role of microvascularization and growth/adhesion-regulatory lectins in the prognosis of non-small cell lung cancer in stage II. Eur J Cardiothorac Surg. 2007;31:783-787.
37. van den Brule FA, Buicu C, Berchuck A, et al. Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol. 1996;27:1185-1191. (Pubitemid 26374939)
38. Baptiste TA, James A, Saria M, et al. Mechano-transduction mediated secretion and uptake of galectin-3 in breast carcinoma cells: implications in the extracellular functions of the lectin. Exp Cell Res. 2007;313:652-664. (Pubitemid 46198812)
39. Endo K, Kohnoe S, Tsujita E, et al. Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer Res. 2005;25:3117-3121.
40. Gimm O, Krause U, Brauckhoff M, et al. Distinct expression of galectin-3 in pheochromocytomas. Ann N y Acad Sci. 2006;1073:571-577. (Pubitemid 44912051)
41. Thompson LDR. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002;26:551-556.